April 29, 2026 — Syngene International Ltd, a leading contract research and manufacturing services (CRAMS) organization, reported its fourth-quarter results today. While the company saw a modest rise in revenue, net profits faced a double-digit decline, largely attributed to specific impacts within its biologics segment.
Financial Performance at a Glance (Q4 FY26)
| Metric | Q4 FY26 | Q4 FY25 | Change (YoY) |
| Revenue from Operations | ₹1,036.5 Cr | ₹1,018 Cr | 📈 1.8% |
| Net Profit (PAT) | ₹147.9 Cr | ₹183.3 Cr | 📉 19.3% |
| EBITDA | ₹303.4 Cr | ₹343.6 Cr | 📉 11.7% |
| EBITDA Margin | 29.3% | 33.8% | 📉 450 bps |
Key Operational Takeaways
-
Full Year Momentum: For the entire fiscal year (FY26), revenue grew 3% to ₹3,739 crore, with an annual EBITDA margin of 25%.
-
Exceptional Items: Excluding exceptional items, PAT for the quarter stood at ₹153 crore.
-
Biologics Impact: CEO Peter Bains noted that the results reflect a specific impact from a single large-molecule biologics client, though the underlying business remains steady.
-
Future Growth Areas: The company is aggressively investing in emerging modalities, including peptides and Antibody-Drug Conjugates (ADCs), along with AI and digital capabilities.
Dividend and Shareholder Information
The Board has recommended a reward for shareholders:
-
Final Dividend: ₹1.25 per equity share (Face Value: ₹10).
-
Record Date: Friday, June 26, 2026.
-
Payment Timeline: Within 30 days of shareholder approval.
Leadership Commentary
Kiran Mazumdar-Shaw, Executive Chairperson, emphasized the company’s resilience:
“Syngene’s diversified end-to-end business model… gives us both resilience and strategic agility. We are focused on building new business lines and investing in AI capabilities that will enhance value creation.”
Peter Bains, Managing Director and CEO, added:
“Performance was in line with our revised full-year guidance… we continued to invest in new capabilities… further strengthening our integrated offering and positioning us for long-term growth.”
Market Update
Following the results, Syngene International Ltd shares traded lower on the BSE, closing at ₹432.30, down 1.75% (₹7.70) in a cautious market.
